Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated medical claim closely and specifically matches the FDA label text for ALBENZA embryo-fetal toxicity (fetal harm warning, avoid use in pregnancy unless no alternative, pregnancy testing, effective contraception during therapy and for one month after, and immediate discontinuation if pregnancy occurs) with correct section alignment.
Category Scores
Accurate Statements
ALBENZA (albendazole) may cause fetal harm.
Section 5.2 Embryo-fetal Toxicity; Section 17 Patient Counseling Information
ALBENZA should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate.
Section 5.2 Embryo-fetal Toxicity; Section 8.1 Pregnancy
Obtain pregnancy test prior to prescribing ALBENZA to women of reproductive potential.
Section 5.2 Embryo-fetal Toxicity; Section 8.3 Females and Males of Reproductive Potential
Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy.
Section 5.2 Embryo-fetal Toxicity; Section 8.3 Females and Males of Reproductive Potential; Section 17 Patient Counseling Information
Immediately discontinue ALBENZA if a patient becomes pregnant and apprise the patient of the potential hazard to the fetus.
Section 5.2 Embryo-fetal Toxicity; Section 8.1 Pregnancy
Unsupported Statements
Contradictions
Important Omissions
The evaluated claim does not mention the label’s limitation that the pregnancy human data are limited (e.g., 'limited data... to inform a drug-associated risk of major birth defects and miscarriage').
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No fetal-harm-related instructions are missing or misstated relative to the label; reproductive-risk management steps included are the core safety actions specified (avoid pregnancy use unless no alternative, pregnancy testing, effective contraception, immediate discontinuation if pregnancy occurs).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement